Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV : Real‐world insights from BICSTaR cohorts
HIV Medicine · 2024-04 · 25 (4) · 440-453
DOI: 10.1111/hiv.13593 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift HIV Medicine, online erschienen am 26.12.2023. Verfasst von Stefan Esser und 17 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Dermatology, Department of Venerology, University Hospital Essen, Essen, Germany. Hauptthemen laut MEDLINE: Alanine, Amides, Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Background
Real‐world evidence is an essential component of evidence‐based medicine. The aim of the BICSTaR (BICtegravir Single Tablet Regimen) study is to assess effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in antiretroviral treatment‐naïve (TN) and treatment‐experienced (TE) people with HIV.
Methods
BICSTaR is a prospective, observational cohort study.
Participants
(≥18 years) are being followed for 24 months. A pooled analysis is presented at 12 months, with the primary endpoint of effectiveness (HIV‐1 RNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinic of Dermatology, Department of Venerology, University Hospital Essen, Essen, Germany.
- Maple Leaf Medical Clinic, Toronto, Ontario, Canada.
- HIV Unit, Hospital Clinic of Barcelona, Barcelona, Spain.
- Infectious Disease Unit, Sheba Medical Center, Israel and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Clinic of Infectious Diseases, Department of Health Sciences, University of Milan, "ASST Santi Paolo e Carlo", Milan, Italy.
- Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland.
ORCID-Profile: Antonella D'Arminio Monforte, Berend van Welzen
Förderung
- Gilead Sciences
Zitieren
APA
Esser, S., Brunetta, J., Inciarte, A., Levy, I., D'Arminio Monforte, A., Lambert, J. S., van Welzen, B., Teruya, K., Boffito, M., Liu, C. E., Altuntas Aydın, O., Thorpe, D., Heinzkill, M., Marongiu, A., Cassidy, T., Haubrich, R., D'Amato, L., & Robineau, O. (2024). Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV : Real‐world insights from BICSTaR cohorts. HIV Medicine, 25(4), 440-453. https://doi.org/10.1111/hiv.13593
Vancouver
Esser S, Brunetta J, Inciarte A, Levy I, D'Arminio Monforte A, Lambert JS, et al. Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV : Real‐world insights from BICSTaR cohorts. HIV Medicine. 2024;25(4):440-453. doi:10.1111/hiv.13593
BibTeX
@article{Esser2024,
author = {Esser, Stefan and Brunetta, Jason and Inciarte, Alexy and Levy, Itzchak and D'Arminio Monforte, Antonella and Lambert, John S and van Welzen, Berend and Teruya, Katsuji and Boffito, Marta and Liu, Chun-Eng and Altuntas Aydın, Ozlem and Thorpe, David and Heinzkill, Marion and Marongiu, Andrea and Cassidy, Tali and Haubrich, Richard and D'Amato, Lisa and Robineau, Olivier},
title = {Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV : Real‐world insights from BICSTaR cohorts},
journal = {HIV Medicine},
year = {2024},
volume = {25},
number = {4},
pages = {440--453},
doi = {10.1111/hiv.13593}
}
EUVIMED